Huiliang Bai, director of the National Pharmaceutical Management Bureau Office says that the areas of pharmaceutical industry in which China encourages foreign businesses to invest are: those that can meet the needs of domestic and foreign markets, upgrade product levels, expand foreign sales, increase exports and foreign currency earnings; enterprises that can produce medicine that cannot be produced by China but is urgently needed; those that can introduce domestically needed advanced technology to reform old enterprises; those that can introduce new high level technology, patent technology and products; and those that bring advanced management experience. 
He says that apart from investment, the Chinese government also welcomes cooperation of foreign pharmaceutical enterprises to cooperate with China in other ways, such as compensation trade, licensing trade, third party processing, technology transfer, and joint development of new products. 
(End)
